Clearly, the cardiologists are experiencing an interpretation bias (or we are!) This dichotomy is not acceptable anymore from a purely scientific perspective. A public dialogue must begin immediately to address this issue for the sake of our patients' lives.
Of all patients who underwent revascularization in ISCHEMIA trial, 5.4% underwent CABG for Duke 6 risk score (severe 3 VD). This was the argument to downgrade CABG. Rest my case.
"The ESC/EACTS document assumes an equipoise between long-term survival of transcatheter aortic valve implantation (TAVI) and SAVR, which is unsupported by findings of most randomized controlled trials (RCTs), meta-analysis, and national databases"
https://t.co/OGLLct25aQ
This paper is our new contribution to investigating biomechanical characteristics of ascending aortic aneurysms related to acute aortic dissection initiation and propagation. Kudos to my resident and postgraduate student E. Kefalidi for a fantastic job! https://t.co/zwKB91ELZU
Just out: our joint surgical statement @EACTS@LATAM_LACES#ASCVTS@AATSHQ@STS_CTsurgery on the #VARC-3 definitions for aortic valve research
🧵
Joint simultaneous publication in our journals: https://t.co/zisS7S6j6v
https://t.co/xDvXG0QqyI
https://t.co/MFUykydPY7
“…the SCAI definition…does not appear to be fit for practice”. SCAI-Defined Perioperative MIs Too Numerous to Be Useful in Cardiac Surgery https://t.co/ajzNMhu5Km
TAVI offers a survival advantage only in the first 6 months, it then becomes a predictor for higher mortality compared to SAVR (increases 18% the risk of death). @kaulcsmc
Letter on behalf of LACES and its Board of Directors regarding the recently published 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. | LACES | Latin American Association of Cardiac and Endovascular Surgery https://t.co/GZyKEKgCgE
@brophyj@VictorDayan1@kaulcsmc@drjohnm@DavidLBrownMD Whereas “the guidelines were reviewed by the AATS and the STS...neither formally endorsed the document.” I think that AATS, STS, and other CT surgical associations worldwide need to react to this “Guile, Duplicity, and Perfidious Publication.”
The mean age for Aortic Valve Replacement is 75 yrs, ( mean survival 10.6 yrs for 70-79 yrs group). So a 75 yrs threshold gives the TAVI "business" access to half of the current AVR population but with unknown long term survival.
@escardio@EACTS
https://t.co/sSpbpcIlO2
...our extensive intact-wall and layer-specific mechanical analysis endorses current therapeutic guidelines suggesting a rather aggressive ATAA replacement strategy for patients with an indication for AV surgery.